The Story of a Much Controversial Drug; Favipiravir

Adem Durmaz; Duru Mıstanoğlu Özatağ

Makale detayları

The Story of a Much Controversial Drug; Favipiravir

Yazarlar:

Adem Durmaz | Duru Mıstanoğlu Özatağ

Yayıncı:

Mersin University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Mersin Üniversitesi Tıp Fakültesi Lokman Hekim Tıp Tarihi ve Folklorik Tıp Dergisi Vol.13 Issue 2, pp.283-292

Belge Tipi:

Makale

Yayın Tarihi:

5/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001290476

pISSN:

1309-8004

Anahtar kelimeler:

Özet:

 Purpose: Favipiravir was distributed free of charge by the Ministry of Health for treatment purposes during the Coronavirus disease Covid-19 pandemic. This study was conducted to investigate the use of this drug by the patients and the factors affecting it. Method: Between January and March 2022 in Kütahya, two hundred and fifty-two patients randomly selected from the patients diagnosed with Covid-19 were reached by telephone. A questionnaire about demographic characteristics and favipiravir use was applied to the volunteers. Results: In our study, it was found that the participants were between the ages of 1-29, 73.6 of them were female and 44.6 of them were university graduates. The number of patients who did not use this drug was 72.3 n107. It was observed that the patients 63.6 n75 did not use favipiravir because they thought it would harm themselves the most. Favipiravir use was found to be at a higher rate in patients aged 46 years and older p0.001, primary school graduate patients with less education years p0.027, non-working patients p0.006 and patients with a recovery period of 8-14 days p0.003. Conclusion: During the Covid-19 Pandemic, favipiravir usage rates remained very low. One of the most important reasons for this is the distrust of this drug. Although the authorities have made statements about this issue, social media and other communication tools have negatively affected people. More effective information programs and prevention of information disinformation on social media are important in order to control and successfully manage such major pandemics.

 Purpose: Favipiravir was distributed free of charge by the Ministry of Health for treatment purposes during the Coronavirus disease Covid-19 pandemic. This study was conducted to investigate the use of this drug by the patients and the factors affecting it. Method: Between January and March 2022 in Kütahya, two hundred and fifty-two patients randomly selected from the patients diagnosed with Covid-19 were reached by telephone. A questionnaire about demographic characteristics and favipiravir use was applied to the volunteers. Results: In our study, it was found that the participants were between the ages of 1-29, 73.6 of them were female and 44.6 of them were university graduates. The number of patients who did not use this drug was 72.3 n107. It was observed that the patients 63.6 n75 did not use favipiravir because they thought it would harm themselves the most. Favipiravir use was found to be at a higher rate in patients aged 46 years and older p0.001, primary school graduate patients with less education years p0.027, non-working patients p0.006 and patients with a recovery period of 8-14 days p0.003. Conclusion: During the Covid-19 Pandemic, favipiravir usage rates remained very low. One of the most important reasons for this is the distrust of this drug. Although the authorities have made statements about this issue, social media and other communication tools have negatively affected people. More effective information programs and prevention of information disinformation on social media are important in order to control and successfully manage such major pandemics.

 Purpose: Favipiravir was distributed free of charge by the Ministry of Health for treatment purposes during the Coronavirus disease Covid-19 pandemic. This study was conducted to investigate the use of this drug by the patients and the factors affecting it. Method: Between January and March 2022 in Kütahya, two hundred and fifty-two patients randomly selected from the patients diagnosed with Covid-19 were reached by telephone. A questionnaire about demographic characteristics and favipiravir use was applied to the volunteers. Results: In our study, it was found that the participants were between the ages of 1-29, 73.6 of them were female and 44.6 of them were university graduates. The number of patients who did not use this drug was 72.3 n107. It was observed that the patients 63.6 n75 did not use favipiravir because they thought it would harm themselves the most. Favipiravir use was found to be at a higher rate in patients aged 46 years and older p0.001, primary school graduate patients with less education years p0.027, non-working patients p0.006 and patients with a recovery period of 8-14 days p0.003. Conclusion: During the Covid-19 Pandemic, favipiravir usage rates remained very low. One of the most important reasons for this is the distrust of this drug. Although the authorities have made statements about this issue, social media and other communication tools have negatively affected people. More effective information programs and prevention of information disinformation on social media are important in order to control and successfully manage such major pandemics.

 Amaç: Koronavirüs hastalığı Covid-19 pandemisinde favipiravir Sağlık Bakanlığı tarafından tedavi amacıyla ücretsiz olarak dağıtılmıştır. Bu çalışmanın amacı, hastaların favipiraviri kullanma durumları ve buna etki eden faktörlerin araştırılmasıdır. Yöntem: Kütahya ilinde Ocak-Mart 2022 tarihleri arasında Covid-19 tanısı almış hastalardan rastgele seçilen iki yüz elli iki hastaya telefon ile ulaşılmıştır. Gönüllü olan hastalara demografik özellikler, favipiravir kullanma durumları ile ilgili bir anket uygulanmıştır. Bulgular: Çalışmamızda katılımcıların 37,2sinin 1-29 yaş arasında, 73.6sının kadın, 44.6sının üniversite mezunuydu. Covid-19 hastalarının 72,3ü n107 bu ilacı kullanmadığını bildirdi. İlacı kullanmayan hastaların 63,6sı n75 bu ilacın kendisi için zararlı olduğu düşündüğü için kullanmadığını belirtti. 46 yaş ve üzeri hastaların p0,001, eğitim yılı az olan ilköğretim mezunu hastaların p0,027, çalışmayan hastaların p0,006 ve iyileşme süresi 8-14 gün olan hastaların p0,003 daha yüksek oranlarda favipiravir kullandığı gözlendi. Sonuç: Covid-19 pandemisi sırasında, favipiravir kullanım oranları, çok düşük düzeylerde kalmıştır. Bunun en önemli sebeplerinden birisi bu ilaca olan güvensizliktir. Her ne kadar yetkililer bu konu hakkında açıklama yapmış olsa da sosyal medya ve diğer iletişim araçları insanları olumsuz yönde etkilemiştir. Bunun gibi büyük pandemilerin kontrol altına alınması ve başarılı bir şekilde yönetilmesi için daha etkin bilgilendirme programları ve sosyal medyada çıkan bilgi dezenformasyonlarına engel olunması önemlidir.

Makale detayları

The Story of a Much Controversial Drug; Favipiravir

Yazarlar:

Adem Durmaz | Duru Mıstanoğlu Özatağ

Yayıncı:

Mersin University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Mersin Üniversitesi Tıp Fakültesi Lokman Hekim Tıp Tarihi ve Folklorik Tıp Dergisi Vol.13 Issue 2, pp.283-292

Belge Tipi:

Makale

Yayın Tarihi:

5/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001290476

pISSN:

1309-8004

Covid-19

Favipiravir

Treatment

Affecting factors.Covid-19

favipiravir

tedavi

etkileyen faktörler.

Sayı

Makale detayları

Yazarlar: Adem Durmaz | Duru Mıstanoğlu Özatağ

Yayıncı: Mersin University

Ana Başlıklar: Klinik Tıp Bilimleri

Dergi: Mersin Üniversitesi Tıp Fakültesi Lokman Hekim Tıp Tarihi ve Folklorik Tıp Dergisi Vol.13 Issue 2, pp.283-292

Belge Tipi: Makale

Yayın Tarihi: 5/2023

Belge Dili: Türkçe

Document ID (Org No.): 2001290476

pISSN: 1309-8004

Sayı

Yazarlar:

Adem Durmaz | Duru Mıstanoğlu Özatağ

Yayıncı:

Mersin University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Mersin Üniversitesi Tıp Fakültesi Lokman Hekim Tıp Tarihi ve Folklorik Tıp Dergisi Vol.13 Issue 2, pp.283-292

Belge Tipi:

Makale

Yayın Tarihi:

5/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001290476

pISSN:

1309-8004